Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer

Abstract

Introduction Patients with nonmetastatic but exceptionally high‐risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen‐deprivation therapy, as first‐line treatment, may control the disease for a long period. Case presentation We treated a patient with super‐high‐risk, nonmetastatic prostate cancer, with triple combination therapy. He was biochemical relapse free at 60 months after the initiation of treatment. Conclusion Triple combination therapy may be an option for super‐high‐risk, nonmetastatic prostate cancer.

Keywords

• androgen‐deprivation therapy
• prostate cancer
• prostatectomy
• radiation therapy